Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of Entity:	Prana Biotechnology Limited (ASX:PBT)
ACN:	080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr. Geoffrey Kempler
Date of Last Notice:	4 th January 2012

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct		
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-		
Date of change	12 th December	r 2012	
No. of securities held prior to		Shares	Options
change	Direct	30,000	-
	Indirect	17,625,000	-
	Total	17,655,000	-
Class	Unlisted Option	ons	
Number acquired		Shares	Options
	Direct	-	4,000,000
	Indirect	-	-
	Total	-	4,000,000

⁺ See chapter 19 for defined terms.

Number disposed			
Tumber disposed		Shares	Options
	Direct	-	=
	Indirect	=	=
	Total	-	-
Value/Consideration	As detailed	in the Explanatory	Memorandum which
Note: If consideration is non-cash, provide details and			the 2012 Notice of
estimated valuation	-	al Meeting of the Con	
	7 Himaar Genera	ii weeting of the con	ipuily.
No. of securities held after change			
8		Shares	Options
	Direct	30,000	4,000,000
	Direct Indirect	30,000 17,625,000	4,000,000
			4,000,000 - 4,000,000
	Indirect	17,625,000	-
Nature of change	Indirect Total	17,625,000 17,655,000	-
Nature of change Example: on-market trade, off-market trade, exercise	Indirect Total Issued in acco	17,625,000 17,655,000 ordance with Resolut	- 4,000,000 ion 5 as approved by
	Indirect Total Issued in acco	17,625,000 17,655,000 ordance with Resolut t the Company's An	4,000,000

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to	
change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A



The CFO Solution

12 Dec 2012

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of Entity:	Prana Biotechnology Limited (ASX:PBT)
ACN:	080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Dr. George Mihaly
Date of Last Notice:	3 rd November 2010

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct		
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-		
Date of change	12 th December	r 2012	
No. of securities held prior to		Shares	Options
change	Direct	166,666	-
	Indirect	60,000	-
	Total	226,666	-
			_
Class	Unlisted Option	ons	
Number acquired		Shares	Options
	Direct	-	1,000,000
	Indirect	-	-
	Total	-	1,000,000

⁺ See chapter 19 for defined terms.

Number disposed				1
Trainer disposed		Shares	Options	
	Direct	-	-	
	Indirect	-	-	
	Total	•	-	
Value/Consideration	As detailed	in the Explanator	y Memorandum wh	nich
Note: If consideration is non-cash, provide details and	accompanied	and formed part	of the 2012 Notice	of
estimated valuation	Annual General Meeting of the Company.			
No. of securities held after change		Shares	Options	
	Direct	166,666	1,000,000	
	Indirect	60,000	-	
	Total	226,666	1,000,000	
	Total	226,666	1,000,000	_
Nature of change		, ,	1,000,000 ution 5 as approved	by
Example: on-market trade, off-market trade, exercise	Issued in acco	ordance with Resol	, ,	•
	Issued in acco	ordance with Resol t the Company's A	ution 5 as approved	•

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to	
change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A



The CFO Solution

12 Dec 2012

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of Entity:	Prana Biotechnology Limited (ASX:PBT)
ACN:	080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr. Peter Marks
Date of Last Notice:	3 rd November 2010

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct		
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-		
Date of change	12 th December	r 2012	
No. of securities held prior to		Shares	Options
change	Direct	-	-
	Indirect	43,111	-
	Total	43,111	-
			_
Class	Unlisted Option	ons	
Number acquired		Shares	Options
	Direct	-	1,000,000
	Indirect	-	-
	Total	-	1,000,000

⁺ See chapter 19 for defined terms.

Number disposed			
Number disposed		Shares	Options
	Direct	=	=
	Indirect	=	=
	Total	-	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	As detailed in the Explanatory Memorandum which accompanied and formed part of the 2012 Notice of Annual General Meeting of the Company.		
No. of securities held after change		Shares	Options
No. of securities held after change	Direct	Shares -	Options 1,000,000
No. of securities held after change	Direct Indirect	Shares - 43,111	
No. of securities held after change		-	
No. of securities held after change	Indirect	43,111	1,000,000
No. of securities held after change Nature of change	Indirect Total	43,111 43,111	1,000,000

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to	
change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A



12 Dec 2012

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of Entity:	Prana Biotechnology Limited (ASX:PBT)
ACN:	080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr. Brian Meltzer
Date of Last Notice:	3 rd November 2010

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct		
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-		
Date of change	12 th December 2012		
No. of securities held prior to		Shares	Options
change	Direct	-	-
	Indirect	326,666	-
	Total	326,666	-
			_
Class	Unlisted Option	ons	
Number acquired		Shares	Options
	Direct	-	1,000,000
	Indirect	-	-
	Total	-	1,000,000

⁺ See chapter 19 for defined terms.

Number disposed		Shares	Options
	Direct	Silaies	Options
	Indirect	-	-
		-	-
	Total	-	-
Value/Consideration	As detailed	in the Explanatory	Memorandum which
Note: If consideration is non-cash, provide details and			f the 2012 Notice of
estimated valuation		al Meeting of the Cor	
	1 111110011 0 0 1101	ar mooning or the oor	p
No. of securities held after change		Chamas	Ontions
No. of securities held after change	D	Shares	Options
No. of securities held after change	Direct	-	Options 1,000,000
No. of securities held after change	Direct Indirect	Shares - 326,666	
No. of securities held after change		-	
No. of securities held after change	Indirect	326,666	1,000,000
No. of securities held after change	Indirect Total	326,666 326,666	1,000,000 - 1,000,000
Nature of change	Indirect Total Issued in acco	326,666 326,666 ordance with Resolut	1,000,000 - 1,000,000
Nature of change Example: on-market trade, off-market trade, exercise	Indirect Total Issued in accesshareholders a	326,666 326,666 ordance with Resolute the Company's Ar	1,000,000 - 1,000,000
Nature of change	Indirect Total Issued in acco	326,666 326,666 ordance with Resolute the Company's Ar	1,000,000 - 1,000,000

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to	
change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A



The CFO Solution

12 Dec 2012

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of Entity:	Prana Biotechnology Limited (ASX:PBT)
ACN:	080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr. Lawrence Gozlan
Date of Last Notice:	9 th August 2011

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct		
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-		
Date of change	12 th December	r 2012	
No. of securities held prior to		Shares	Options
change	Direct	Silaies	Options
		-	-
	Indirect	-	-
	Total	-	-
Class	Unlisted Option	ons	
Number acquired		Shares	Options
	Direct	-	1,000,000
	Indirect	-	-
	Total	-	1,000,000

⁺ See chapter 19 for defined terms.

Number disposed				
Number disposed		Shares	Options	
	Direct	=	-	
	Indirect	=	-	
	Total	-	-	
	-			
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	As detailed in the Explanatory Memorandum which accompanied and formed part of the 2012 Notice of Annual General Meeting of the Company.			
No. of securities held after change		Shares	Options	
	Direct	-	1,000,000	
	Indirect	-	-	
	Total	-	1,000,000	
Nature of change	Issued in accordance with Resolution 5 as approved by			
- ····		shareholders at the Company's Annual General Meeting held on 12 th December 2012.		

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to	
change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A



The CFO Solution

12 Dec 2012

⁺ See chapter 19 for defined terms.